AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

69.95USD
1:32am IST
Change (% chg)

$0.22 (+0.32%)
Prev Close
$69.73
Open
$70.06
Day's High
$70.39
Day's Low
$69.68
Volume
1,461,302
Avg. Vol
2,560,666
52-wk High
$71.59
52-wk Low
$51.40

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease; hepatitis C (HCV);... (more)

Overall

Beta: --
Market Cap(Mil.): $111,085.20
Shares Outstanding(Mil.): 1,593.08
Dividend: 0.51
Yield (%): 2.93

Financials

  ABBV.N Industry Sector
P/E (TTM): 54.54 36.80 40.04
EPS (TTM): 1.28 -- --
ROI: -- 16.38 15.66
ROE: -- 17.14 16.66
Search Stocks

Drugmaker Shire bids $30 billion for Baxter spin-off Baxalta

LONDON - Drugmaker Shire said on Tuesday it was seeking to buy Baxalta , a company spun-off by Baxter International last month, for $30 billion to forge the leading global specialist in rare diseases.

1:52am IST

Drugmaker Shire bids $30 billion for Baxter spin-off Baxalta

LONDON - Drugmaker Shire said on Tuesday it was seeking to buy Baxalta , a company spun-off by Baxter International last month, for $30 billion to forge the leading global specialist in rare diseases. | Video

1:39am IST

BRIEF-Ablynx initiates phase II SLE study with its anti-IL-6R Nanobody

* Ablynx initiates phase II SLE study with its anti-IL-6R Nanobody, partnered with Abbvie Inc

04 Aug 2015

AbbVie, Bristol-Myers get FDA nod for hep C treatments

- The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus (HCV) infections.

25 Jul 2015

CORRECTED-UPDATE 2-AbbVie, Bristol-Myers get FDA nod for hep C treatments

July 24 - The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus (HCV) infections.

25 Jul 2015

AbbVie hepatitis C cocktail succeeds in late-stage study

- AbbVie Inc said on Wednesday that its hepatitis C cocktail Viekira Pak was effective whether or not it was used in combination with the compound ribavirin against the most common form of the disease, according to data from a late-stage study.

24 Jun 2015

UPDATE 1-AbbVie hepatitis C cocktail succeeds in late-stage study

June 24 - AbbVie Inc said on Wednesday that its hepatitis C cocktail Viekira Pak was effective whether or not it was used in combination with the compound ribavirin against the most common form of the disease, according to data from a late-stage study.

24 Jun 2015

AbbVie hepatitis C cocktail succeeds in late-stage study

June 24 - AbbVie Inc said on Wednesday that all patients in a late-stage study showed a sustained response to its cocktail of hepatitis C treatments, currently sold in the U.S. as Viekira Pak.

24 Jun 2015

Borrowers warned: Don't be fooled by high grade market resilience

NEW YORK, May 11 (IFR) - Apple, Shell and AbbVie blitzed the US bond market last week with a combined US$34bn of jumbo bond deals in just two days, bringing the week's tally to US$52bn, the fourth-largest of all time.

11 May 2015

Drugmaker AbbVie's profit beats estimates on strong Humira sales

- U.S. drugmaker AbbVie Inc reported better-than-expected quarterly profit and revenue, driven by strong sales of its arthritis drug, Humira.

23 Apr 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $99.80 -0.22
Pfizer Inc. (PFE.N) $36.11 -0.04
Novartis AG (NOVN.VX) CHF100.80 -0.30
Merck & Co., Inc. (MRK.N) $58.70 -0.35
Roche Holding Ltd. (ROG.VX) CHF280.00 +0.40
Abbott Laboratories (ABT.N) $50.51 +0.01
Eli Lilly and Co (LLY.N) $84.05 -0.09

Earnings vs. Estimates

Search Stocks